Copyright: convisum / 123RF Stock Photo

Direct-acting antiviral (DAA) treatment of hepatitis C virus (HCV) infection in patients with chronic kidney disease (CKD) has made transplantation of kidneys from HCV-infected donors to uninfected recipients (D+/R−) feasible. In a study recently published in AJKD, Craig E. Gordon et al conducted a systematic review of HCV D+/R− kidney transplantation coupled with DAA treatment.

AJKDBlog’s Interviews Editor, Timothy Yau @Maximal_Change, recently caught up with his colleagues, Bea Concepcion @KidneyBea_n and Rachel Forbes @rachel_c_forbes, for a deeper dive.

If the embedded player above doesn’t work, please click here to watch the video interview. Special thanks to Drs Concepcion and Forbes for agreeing to do the interview!

Forest plot of SVR12 with DAA treatment for HCV-infected donor to HCV-uninfected recipient kidney transplantation. Figure 1 from Gordon et al, AJKD © National Kidney Foundation.

To view this Original Investigation (Open Access), please visit AJKD.org

Title: Kidney Transplantation From Hepatitis C Virus–Infected Donors to Uninfected Recipients: A Systematic Review for the KDIGO 2022 Hepatitis C Clinical Practice Guideline Update
Author: Craig E. Gordon, Gaelen P. Adam, Michel Jadoul, Paul Martin, and Ethan M. Balk
DOI: 10.1053/j.ajkd.2022.12.019